而Luminal B、Her-2阳性、三阴性患者未能从放疗中获益 研究结论:术后放疗可以给T1-2N1M0 Luminal A 型乳腺癌患者带来生存获益 我的二维码 参考文献 Wei J,Jiang Y,Shao Z.The survival benefit of postmastectomy radiotherapy for breast...
21-Gene Recurrence Score Assay Predicts Benefit of Post-Mastectomy Radiotherapy in T1-2 N1 Breast Cancer. Clin Cancer Res; 24(16); 3878–87.
结果 73 421例女性患者中 N0期 61 955例(84.4%),N1期 9 995例(13.6%),N2期 1 087例(1.5%),N3期384例(0.5%)。浸润性癌、组织学分级3级、T1c期、孕激素受体(PR)阳性、分子分型为人类表皮生长因子受体2(HER‑2)阳性患者更易发生淋巴结转移(均P<0.05)。中位随访时间55个月,T1期乳腺癌患者5年生存...
Protein tyrosine kinase activity in 350 T1=T2, N0=N1 breast cancer: preliminary results. Breast Cancer Res Treat. 1996;39:327^334.Protein tyrosine kinase activity - Bolla, Rostaing-Puissant, et al. - 1996Bolla, M.; Rostaing-Puissant, B.; Bottari, S.P.; Chedin, M.; Marron-Charriere, ...
摘要: 目的:评估乳腺癌根治术后放疗(post-mastectomy radiation therapy,PMRT)在早期(T1-2N1)三阴型乳腺癌(triple negative breast cancer,TNBC)患者中的治疗价值.方法:回顾性分析SEER数据库中根治术后早期(pT1-2N1)TNBC患者的临床数据.将患者分为根治术后放疗(PMRT)组和无放... 查看全部>>关键词:...
Breast-conserving surgery (BCS) plus radiotherapy and mastectomy exhibit highly comparable prognoses for early-stage breast cancer; however, the safety of
and discussed the correlation of the various factors with axillary lymph node metastasis of T1 breast cancer.Results One hundred and thirty-nine were the node nega-tive group (T1N0)and the remaining 67 cases were allotted to the node positive group (T1N1-3),age (χ2 = 6.484,...
对于T1-2N1的早期乳腺癌患者,全乳切除术后是否进行放疗仍存争议。目前认为对于一部分低风险乳腺癌患者,全乳切除术后放疗的潜在远期毒性可能超过其获得的潜在局部复发率上的获益。目前的指南也推荐全乳切除术后放疗主要用于高风险女性。近日发布在Clinical Cancer Research杂志上的一项研究,分别纳入NCDB和SEER数据库患者,...
The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125 I EGF to tumor plasma memb...
From June 1982 to December 1992, 415 patients under 75 years of age, without any previous or synchronous carcinoma, suffering from an invasive breast cancer classified as T1 (52.8%), T2 (47.2%), N0 (65.1%) N1 (34.9%), MO according to clinical TNM staging, were enrolled in this study....